Hepatitis B virus

Excision BioTherapeutics Announces Oral Presentation Highlighting Positive Data from its HBV Program, EBT-107, at the Upcoming ASGCT 2024 Annual Meeting

Retrieved on: 
월요일, 4월 22, 2024
CRISPR, Infection, LNP, Hepatitis B virus, RNA, Cell, Viral, CccDNA, DNA, Viral load, Gene, Society, Serum, Genome, Messenger, Biomarker, Annual general meeting, SAN, HBV, Vaccine

HBV is one of the most prevalent infectious diseases worldwide that lacks curative therapies.

Key Points: 
  • HBV is one of the most prevalent infectious diseases worldwide that lacks curative therapies.
  • While existing antiviral and immunomodulator treatments slow liver damage by reducing viral load, they fail to eliminate covalently closed circular DNA (cccDNA) that enables persistent viral infection.
  • Excision’s lead product candidate for the treatment of HBV infection, EBT-107, uses dual guide RNAs to effectively deactivate the virus and prevent the emergence of escape variants.
  • Testing a selected combination of editing nucleases and paired guide RNAs in HBV-infected cells, we observed decreased copies of total HBV DNA.

Excision BioTherapeutics Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Retrieved on: 
수요일, 4월 10, 2024
Abstract, Annual general meeting, CRISPR, SAN, AAV, Hepatitis B virus, HBV

SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc. (“Excision”, the “Company”), a clinical-stage biotechnology company developing CRISPR-based therapies to cure serious latent viral infectious diseases, today announced presentation of six abstracts at the ASGCT 2024 Annual Meeting, which is being held from May 7-11, 2024 in Baltimore, Maryland.

Key Points: 
  • SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc. (“Excision”, the “Company”), a clinical-stage biotechnology company developing CRISPR-based therapies to cure serious latent viral infectious diseases, today announced presentation of six abstracts at the ASGCT 2024 Annual Meeting, which is being held from May 7-11, 2024 in Baltimore, Maryland.
  • The presentations are related to new data for the Company’s emerging preclinical programs for herpes simplex virus-1 keratitis (HSV-1 Keratitis) and hepatitis B virus (HBV), as well as an overview of a next generation AAV delivery vector.
  • In addition, there will be an update on the Company’s first-in-human study of EBT-101.

GSK3528869A (Bepirovirsen) for Chronic Hepatitis B Drug Pipeline Research 2024: Market Size, Forecast, and Emerging Insights 2019-2032 - ResearchAndMarkets.com

Retrieved on: 
목요일, 4월 18, 2024
Research, Infectious Diseases, Chemicals, Plastics, Clinical Trials, Manufacturing, Biotechnology, Pharmaceutical, Health, Science, Other Science, Hepatocyte, Protein, SWOT, Hepatitis, TLR8, EU4, Group C, RNA, Toll-like receptor 8, Disease, MPL, GSK, Hepatitis B virus, HBcAg, Immune system, Clinical trial, HBV, Vaccine

The report provides comprehensive insights about GSK3528869A Bepirovirsen for chronic hepatitis B in the seven major markets and China.

Key Points: 
  • The report provides comprehensive insights about GSK3528869A Bepirovirsen for chronic hepatitis B in the seven major markets and China.
  • Other emerging products for chronic hepatitis B are expected to give tough market competition to GSK3528869A Bepirovirsen and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of GSK3528869A Bepirovirsen in chronic hepatitis B.
  • What are the other emerging products available and how are these giving competition to GSK3528869A Bepirovirsen for chronic hepatitis B?

Beckman Coulter's DxI 9000 Immunoassay Analyzer Extends Menu with New CE-Marked Hepatitis Assays at ESCMID Global

Retrieved on: 
화요일, 4월 16, 2024
Infection, HBsAg, Congress, WHO, Hepatitis B, Laboratory, World Health Organization, Hepatitis, Blood, DirectX, ESCMID, DXS, Disease, Senior, Patient, Analyser, Access, Cirrhosis, Hepatitis B virus, Serum, Beckman Coulter, Diagnosis, Chemistry, Liver cancer, Plasma, HBV, Vaccine

Recently, tests for Hepatitis B and C viruses — namely Access anti-HCV, Access HBsAg, and Access HBsAg Confirmatory assays — received CE marks.

Key Points: 
  • Recently, tests for Hepatitis B and C viruses — namely Access anti-HCV, Access HBsAg, and Access HBsAg Confirmatory assays — received CE marks.
  • Detection of the viral surface antigen (HBsAg) in serum or plasma indicates an infection caused by hepatitis B virus (HBV).
  • Building on the strengths and global success of the DxI 9000 Analyzer, Beckman Coulter is elevating efficiency and confidence for hepatitis testing.
  • According to Kathleen Orland, Senior Vice President, General Manager, Chemistry and Immunoassay for Beckman Coulter Diagnostics, "By launching these new hepatitis assays on our DxI 9000 Analyzer, we can deliver exceptional quality.

Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
수요일, 3월 27, 2024
Research, Blood pressure, Body composition, LDL, Adipose tissue, Obesity, Development, Cirrhosis, Three Months, Exercise, Arrhythmia, Hepatitis B virus, Diabetes, Lipid, Patient, Heart rate, Fast Track, Weight loss, Sarcopenia, MASH, Woman, Diet, Investment, Fibrosis, Safety, Optimism, FDA, Triglyceride, IMPACT, Dietary supplement

“We are extremely pleased with the results of the body composition analysis from our recently completed MOMENTUM 48-week Phase 2 obesity trial of pemvidutide.

Key Points: 
  • “We are extremely pleased with the results of the body composition analysis from our recently completed MOMENTUM 48-week Phase 2 obesity trial of pemvidutide.
  • “There is a growing appreciation that the quality of weight loss is as important as the quantity of weight loss.
  • Achieved mean weight loss of 15.6% on 2.4 mg dose of pemvidutide at week 48, with weight loss continuing at the end of treatment.
  • Financial Results for the Three Months Ended December 31, 2023
    Altimmune had cash, cash equivalents and short-term investments totaling $198.0 million at December 31, 2023.

Sepsis Drug Pipeline Research Report 2024: Insights from 30 Companies and 35 Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
화요일, 2월 27, 2024
Pharmaceutical, Health, Clinical Trials, Therapy, Acquisition, Blood pressure, HBV, HCV, Hepatitis B virus, Heparin, CRISPR, Infection, Escherichia coli, Melanoma, News, Cancer, Liver cancer, Discovery, Cell, Vaccine, Intensive care medicine, Adrenomedullin, ADM, COVID, Fungal infection, Patient, Protein, Clinical trial, Survival, Endothelium, NDA, Histone, Thymosin

This report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Sepsis pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Sepsis pipeline landscape.
  • A detailed picture of the Sepsis pipeline landscape is provided which includes the disease overview and Sepsis treatment guidelines.
  • This segment of the Sepsis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sepsis drugs.

Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones

Retrieved on: 
금요일, 1월 5, 2024
Book, Immune system, IND, PD-1, HBV, HPV, Prostate cancer, Nivolumab, Record, Clinical trial, Cancer, NUC, Bank statement, SNAP, Hepatitis B virus, Human papillomavirus infection, Safety, Autoimmunity, APOLLO, Vaccine

OXFORD, United Kingdom, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today provided a preliminary financial update and announced its 2024 corporate objectives.

Key Points: 
  • OXFORD, United Kingdom, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today provided a preliminary financial update and announced its 2024 corporate objectives.
  • Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.
  • “2024 promises to be another exciting year for Barinthus Bio, with multiple data readouts expected across our hepatitis B virus (HBV) infection, human papillomavirus (HPV) infection and prostate cancer programs, as well as the planned initiation of the first in human study of our SNAP platform-based candidate VTP-1000 in Celiac Disease,” said Gemma Brown, Chief Financial Officer of Barinthus Bio.
  • * Barinthus Bio has worldwide rights for all product candidates.

MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline

Retrieved on: 
수요일, 1월 3, 2024
SPL, Hepatitis B virus, Partnership, Hepatocellular carcinoma, Immune system, Research, TCR, Lion, HBV, Cell engineering, MBA, Laboratory, Viral, Cancer, Patient, Safety, Therapy, Vaccine

This partnership will enhance MaxCyte's presence in Asia, with anticipated expansion into the US and European markets.

Key Points: 
  • This partnership will enhance MaxCyte's presence in Asia, with anticipated expansion into the US and European markets.
  • Under the terms of the agreement, Lion TCR obtains worldwide non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.
  • “We are thrilled to partner with Lion TCR to support the development of their TCR-T cell therapies for hepatocellular carcinoma and life-threatening viral infections,” said Maher Masoud, President and CEO of MaxCyte.
  • Lion TCR is MaxCyte’s 24th strategic partnership overall, each of which generates pre-commercial milestone revenue and the vast majority of which include sales-based payments.

Human medicines European public assessment report (EPAR): Blitzima, rituximab, Date of authorisation: 13/07/2017, Revision: 20, Status: Authorised

Retrieved on: 
화요일, 1월 2, 2024
Marketing, INN, Risk, MPA, Shivering, CD20, PML, ACR20, Pemphigus vulgaris, Cancer, Inflammation, Death, Infection, Anatomy, IIA, Skin, Chills, Fever, ATC, Bone marrow, GPA, Disease, Allergy, Hepatitis B virus, CLL, NHL, Safety, Arthritis, Patient, Medical Subject Headings, Cyclophosphamide, Immune system, Antibody, Vincristine, International, Language, Mouth, Follicular lymphoma, Microscopic polyangiitis, Select, Encephalitis, Medicine, B cell, Prednisolone, Autoimmune disease, CHOP, Blood, Rheumatoid arthritis, Vasculitis, European Medicines Agency, Doxorubicin, Cell, Chronic lymphocytic leukemia, Resuscitation, Medical device

Human medicines European public assessment report (EPAR): Blitzima, rituximab, Date of authorisation: 13/07/2017, Revision: 20, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Blitzima, rituximab, Date of authorisation: 13/07/2017, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Truxima, rituximab, Date of authorisation: 17/02/2017, Revision: 21, Status: Authorised

Retrieved on: 
화요일, 1월 2, 2024
Marketing, INN, Risk, MPA, Shivering, CD20, PML, ACR20, Pemphigus vulgaris, Cancer, Inflammation, Death, Infection, Anatomy, IIA, Skin, Chills, Fever, ATC, Joint, Bone marrow, GPA, Disease, Pemphigus, Allergy, B cell, Hepatitis B virus, Glucocorticoid, NHL, CLL, Safety, Rheumatoid arthritis, Arthritis, Patient, Medical Subject Headings, Cyclophosphamide, Immune system, Granuloma, Antibody, Vincristine, International, Language, Blood, Mouth, Follicular lymphoma, Microscopic polyangiitis, Select, Methotrexate, Prednisolone, Autoimmune disease, TNF, CHOP, Vasculitis, European Medicines Agency, Doxorubicin, Cell, Chronic lymphocytic leukemia, Resuscitation, DMARD, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Truxima, rituximab, Date of authorisation: 17/02/2017, Revision: 21, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Truxima, rituximab, Date of authorisation: 17/02/2017, Revision: 21, Status: Authorised